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This thesis describes multiple studies with the aim to examine current health status 
assessment in patients with COPD and ultimately also to give advice on more 
adequate health status assessment. The results will be valorized in the current 
chapter, in which valorization means “the process of creating value from 
knowledge, by making knowledge suitable and/or available for social (and/or 
economic) use and by making knowledge suitable for translation into competitive 
products, services, processes and new commercial activities”. 
RELEVANCE 
Care for patients with COPD can only be optimally provided when being aware of 
the systemic effects of COPD. This thesis showed that an impaired health status is 
present is all healthcare settings, while the current management of COPD is not 
very effective and suboptimal. Therefore, the recommendation to focus on detailed 
characterization of patients with COPD is critical to be able to provide targeted 
care. Previous research showed that interaction between patients and professionals, 
and proactive care improve the diagnostics of (an impaired) health status in 
patients with COPD. The CAT is developed to improve the communication 
between the patient and clinician. So, for both the clinician as the patient, the CAT 
is an easy tool to enhance awareness of symptoms. Though, treatment can vary 
when applying various questionnaires. Different threshold values for symptom 
questionnaires can result in misclassification and, in turn, different treatment 
recommendations. Therefore, this thesis examined the best fitting GOLD cut-
points suggested to provide consistency and transparency in health care for 
patients with COPD. Besides the application of proactive care and consistent cut-
points, evaluation of care is critical. It is necessary to determine the treatment 
efficacy and examine if an intervention has sufficient responsiveness, otherwise 
treatment might erroneously be judged effective. 
TARGET GROUPS 
Primarily the current results are important for health care providers, as 
professionals should be aware of disease burden, possible consequences and most 
suitable treatment options for patients with COPD. Also, patients with COPD 
should be aware of the importance to communicate with their clinician and have a 
say on which treatment they prefer to receive. Furthermore, guideline committees 
are a target group, as they should be informed about the current findings and could 
take these results into consideration for future recommendations.  
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Healthcare providers 
This thesis emphasizes the need for detailed characterization of individuals with 
COPD and for a more tailored treatment, independent of the healthcare setting. In 
order to develop and evaluate effective treatment for patients with COPD, 
individualized assessment is required. A better understanding of the presence and 
possible consequences of an impaired health status is important to recognize and 
respond to these symptoms. Therefore, healthcare professionals need to regularly 
assess symptoms in patients with COPD. Following, awareness of an impaired 
health status will make them able to inform, refer and advise a patient with COPD 
about possible treatment options. When clinicians from primary, secondary and 
tertiary care work together, they will be able to efficiently provide individualized 
care based on the patients’ needs. The present thesis also gives important insights 
for healthcare providers. They should be aware of the fact that the choice of 
symptom measure influences classification, and, in turn, also specific treatment 
recommendation in patients with COPD. 
Patients with COPD 
The application of the new cut-points would re-classify about one-third of the 
patients with COPD. Because possible changes in COPD guidelines impact 
individual disease management, patients should be more involved in their own 
health status assessment. They need to be aware of the physical, mental and social 
impact of COPD. Previous research showed that patients are more likely to change 
their behaviour, when they have more knowledge about the disease and are more 
self-aware. Self-evaluation (tracking whether relevant changes have occurred in 
their disease symptoms) will increase the possibility to receive proper treatment 
and maintain independency, autonomy and adaptability. Patients should see the 
importance of communicating about their symptoms to the clinician.  
Guideline committees 
Previous research showed that the mMRC is a strong and independent predictor of 
all-cause mortality. Furthermore, former studies implied that a CAT cut point of >18 
points more adequately predicts all-cause mortality. It also comprehensively 
categorizes patients with COPD according to the GOLD classification, which is in 
agreement with the findings of the current thesis. Guidelines committees may need 
to consider the use of a mMRC dyspnea grade two or higher, a CAT total score of 
18 points or higher, a CCQ total score of 1.9 points or higher, or a total SGRQ score 
of 46.0 points or higher to classify patients with COPD as symptomatic. These cut-
points enable healthcare professionals to classify the largest proportion of patients 
into the same GOLD quadrant regardless of their choice of symptom measure. 
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ACTIVITIES AND/OR PRODUCTS 
Dissemination of the results is an important part of the valorization of a thesis. 
The results have led to multiple original articles in leading scientific national and 
international journals. The first findings of the current study were presented in 
2014 during the Netherlands Respiratory Society (NRS) 6th Young Investigator 
Symposium (Amsterdam, Netherlands) with the abstract entitled “Functional 
status, mood status and health status in healthy individuals and patients with 
COPD treated in primary care, secondary care or tertiary care setting”. During the 
European Respiratory Society (ERS) congress in 2015, the abstract entitled 
“Health status in patients with COPD and care provided in various healthcare 
settings” was demonstrated with a poster presentation (Amsterdam, Netherlands). 
Furthermore, results have been presented during courses and workshops organized 
by CIRO and other institutes.  
 
Besides the above-mentioned dissemination of the current thesis, it is critical that 
future research is able to emerge from this perspective and show additional results 
in contrast or complementary to these findings. Guideline committees can only 
make influencing decisions when multiple studies show consequences of the 
current cut-points and verify new cut points. The same counts for healthcare 
providers to be able to apply the suggested recommendations for patients with 
COPD. The current thesis will be made available to a wider public.  
INNOVATION 
The following paragraph describes the added value of the results for the industry, 
whereby a distinction is made between the disease burden of COPD, GOLD 
strategy and evaluation of care. 
Disease burden of COPD 
This thesis demonstrated that subjects with mild-to-moderate COPD have an 
impaired health status. Patients with COPD have a reduced physical performance, 
a more impaired disease specific health status and are socially deprived compared 
to non-COPD subjects. This emphasizes the need for detailed characterization of 
individuals with COPD and for a more tailored treatment. The current thesis is 
also the first to reveal the need for additional interventions in secondary care 
patients who remain symptomatic despite pharmacologic and non-pharmacologic 
treatment, while another proportion of low symptomatic secondary care patients 
would allow for de-intensification of care. Moreover, complementing to the 
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current COPD care, it is suggested to detect COPD in the general population by 
performing spirometry and measuring functional status and health status in 
subjects with an increased risk. 
GOLD strategy 
Nowadays, the GOLD strategy determines high symptoms by using various 
questionnaires: the mMRC, (grade 2 or higher), the CCQ (1 point or higher), the 
CAT (10 points or higher), and the SGRQ (25 points or higher). At the start of this 
thesis, the impact of the suggested tools for symptoms of COPD and the different 
definitions of future risk on the frequency distribution and clinical characteristics 
of the GOLD groups remained unknown. The present dissertation shows that the 
choice of symptom measure impacts the classification of patients with COPD in 
GOLD A/C or B/D groups. It is the first to show normative values for CAT in a 
Dutch population (based on the 95th percentile of the CAT in a non-COPD 
population), resulting in a new CAT cut-point of >18 points to indicate an 
impaired health status. Supplementary, the present thesis recommends application 
of newly determined cut-points (with the mMRC as point of reference): mMRC 2 
points; CAT 18 points; CCQ 1.9 points; and SGRQ 46 points. The current thesis 
also shows that the current GOLD cut-points give an underrepresentation of 
patients classified in groups A/C, compared with the newly derived points.  
Evaluation of care 
Previous studies already examined the responsiveness of the SGRQ, CAT, CCQ, 
and HADS to pulmonary rehabilitation in patients with COPD. Though, a 
variance in MCID estimates was observed, leading to a need for verification of the 
MCID estimates of the CAT, CCQ and HADS-A/D. It seemed reasonable to 
conclude that a change of -0.4 points in CCQ and a change of -1.5 points in 
HADS-A/D could be defined as clinically relevant. In contrast, MCIDs of the 
CAT were not comparable between studies, indicating that the CAT is possibly 
more sensitive for external influences than CCQ and HADS-A/D. Therefore, a 
new MCID range for CAT of -3.0 to -2.0 points is proposed.  
  
   
